Mabion S.A. (WSE:MAB)

Market Cap	124.93M -7.0%
Revenue (ttm)	17.61M +56.7%
Net Income	-56.62M
EPS	-3.50
Shares Out	16.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,293
Open	7.80
Previous Close	7.71
Day's Range	7.71 - 7.90
52-Week Range	6.70 - 10.00
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 17, 2026

About Mabion

Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 204
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: MAB

Financial Performance

In 2025, Mabion's revenue was 15.76 million, a decrease of -77.17% compared to the previous year's 69.02 million. Losses were -62.61 million, 888.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 4, 2026

Data Sources Report a data error